Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Zimmer Biomet Stock Performance
NYSE:ZBH opened at $107.87 on Friday. The company has a fifty day simple moving average of $105.55 and a two-hundred day simple moving average of $107.22. The company has a market cap of $21.47 billion, a price-to-earnings ratio of 24.24, a price-to-earnings-growth ratio of 1.95 and a beta of 1.02. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 52 week low of $97.69 and a 52 week high of $133.90.
Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the prior year, the company earned $2.20 earnings per share. As a group, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.
Zimmer Biomet Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.89%. Zimmer Biomet's payout ratio is currently 21.57%.
Hedge Funds Weigh In On Zimmer Biomet
Institutional investors and hedge funds have recently modified their holdings of the company. Siemens Fonds Invest GmbH lifted its position in Zimmer Biomet by 561.8% in the fourth quarter. Siemens Fonds Invest GmbH now owns 15,002 shares of the medical equipment provider's stock valued at $1,585,000 after acquiring an additional 12,735 shares during the last quarter. Menard Financial Group LLC purchased a new stake in Zimmer Biomet in the fourth quarter valued at $30,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Zimmer Biomet in the fourth quarter valued at $14,432,000. Jefferies Financial Group Inc. lifted its position in Zimmer Biomet by 28.4% in the fourth quarter. Jefferies Financial Group Inc. now owns 18,680 shares of the medical equipment provider's stock valued at $1,973,000 after acquiring an additional 4,133 shares during the last quarter. Finally, Integrated Advisors Network LLC lifted its position in Zimmer Biomet by 12.3% in the fourth quarter. Integrated Advisors Network LLC now owns 4,022 shares of the medical equipment provider's stock valued at $425,000 after acquiring an additional 441 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts have recently commented on the company. Stifel Nicolaus raised their target price on Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a research report on Thursday, January 23rd. Raymond James lowered their price objective on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. JMP Securities reiterated a "market outperform" rating and issued a $140.00 price objective on shares of Zimmer Biomet in a report on Friday, February 7th. Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, Royal Bank of Canada reduced their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $124.15.
Check Out Our Latest Stock Report on ZBH
About Zimmer Biomet
(
Get Free Report)
Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
